Technology
RIVET platform
RIVET is a small-molecule modality that controls translation through RNA-guided induced proximity, designed to enable selective suppression of marked transcripts while leaving global translation largely intact.
Translation control should be local
Biology already differentiates transcripts through RNA-binding proteins and RNA structure, creating “addresses” that can be leveraged to focus effects where they matter.
RNA-guided induced proximity
By bringing functional elements together at specific RNA–protein assemblies, we aim to achieve tunable, reversible modulation without requiring destructive mechanisms.
Drug-like delivery
We prioritize small-molecule properties suitable for scalable manufacturing and clinically practical dosing, while building flexibility for follow-on programs.
Approach
Built on converging capabilities
Our approach integrates a chemistry toolkit, transcriptome-scale RNA maps, and validated induced-proximity paradigms to make translation control tractable in drug discovery.
Chemistry toolkit
We focus on ligandable components and modular linker strategies to explore design space efficiently, while protecting proprietary details off-site.
RNA maps
Transcriptome-scale datasets enable a hypothesis-driven view of RNA–protein binding “ZIP codes,” supporting selectivity considerations early in discovery.
Proximity paradigm shift
Induced proximity has been clinically de-risked across modalities, and non-degrading proximity is emerging as a powerful way to modulate function with precision.
Differentiation
Why RIVET
Selectivity emerges from biology, not synthetic design alone, and the modality is designed to be reversible, tunable, and non-destructive.
Versus broad translation inhibitors
Traditional approaches can be limited by global translation shutdown and toxicity. Our objective is localized pharmacology at specific RNA–protein assemblies.
Versus oligonucleotide approaches
We aim for small-molecule-like PK/PD and manufacturability while still addressing transcript-level control, without requiring sequence-dependent therapeutic formats.
Versus degraders
For short-lived proteins, resynthesis can outpace degradation. Translation control can directly modulate production rates and enable rapid functional effects.
Contact
What we share publicly
We keep this site intentionally high-level while we build. Detailed scientific materials are available under NDA.